Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: stockdoc77 who wrote (62968)	12/12/2024 8:36:36 AM
From: plhky3465	2 Recommendations Recommended By jhcimmu summer_sky Read Replies (1) \| Respond to of 63305

How many Insurance companies are going to pay $3 million for this? Is Medicare going to pay $3 million? Or will the patients ever reach the age to receive Medicare?

To: stockdoc77 who wrote (62968)	12/12/2024 9:04:53 AM
From: summer_sky	1 Recommendation Recommended By Davidoff Respond to of 63305

I agree with the assessment about BLUE. The one thing I would add is the two patients in the early trials who developed cancer were part of a different Vector process??. Since the change there haven't been any patients with cancer. I like the buyout projection of around $1 billion. There are thousands in the middle-east and millions in India suffering from sickle cell. An international partner could do wonders to "transform patients lives" to a pain-free enviornment. The inept management should be sharing the recently published long term results with the FDA to have the Black Box removed. Unfortunately, management has run this into the ground and now we are on the eve on a 1:20 reverse split. Its a shame from an investors standpoint to see a company successfully Navigate the FDA process (3x) and they can't or care to produce shareholder value. Summer